Grapiprant is the pioneer member of the novel piprant class, a potent and specific antagonist of the prostaglandin E2 receptor 4. It has been approved in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs at the dose regimen of 2 mg/kg once a day by the FDA and EMA (for pain only) in 2016 and 2018, respectively. The aim of this narrative review was to report the analytical methods, pharmacokinetics, pharmacodynamics and safety of grapiprant in several animal species using the best available published scientific evidence. In conclusion, most of the analytical methods proposed for grapiprant detection are simple, reliable, sensitive and validated. The pharmacokinetics show discrepancies between animal species. The therapeutic efficacy seems more suited to chronic rather than acute pain.

中文翻译：

---

Grapiprant：当前知识的快照

Grapiprant 是新型 piprant 类的先驱成员，它是前列腺素 E2 受体 4 的强效特异性拮抗剂。它已被批准用于兽医学，用于控制与狗骨关节炎相关的疼痛和炎症，剂量方案为 2 mg/分别在 2016 年和 2018 年由 FDA 和 EMA （仅用于疼痛）每天一次。这篇叙述性综述的目的是利用已发表的最佳科学证据，报告几种动物物种中 grapiprant 的分析方法、药代动力学、药效学和安全性。总之，大多数为抓手检测提出的分析方法简单、可靠、灵敏且经过验证。药代动力学显示动物物种之间的差异。治疗效果似乎更适合慢性疼痛而不是急性疼痛。